DYN

Dyne Therapeutics, Inc. is a clinical-stage muscle disease company focused on developing life-transforming therapies for people with genetically driven diseases. The company's proprietary FORCE platform enables the targeted delivery of therapeutic payloads to muscle tissue, potentially overcoming limitations of traditional approaches. Dyne is developing a pipeline of muscle-targeted therapeutics for myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD), and facioscapulohumeral muscular dystrophy (FSHD). The company's lead programs use antisense oligonucleotides and other therapeutic modalities precisely delivered to muscle cells. Dyne's approach aims to improve efficacy and reduce off-target effects compared to systemic delivery methods.